By: Mike Strahan On July 16, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule that has the potential to significantly impact how 340B drugs are handled under Medicare Part D, and by extension, how pharmaceutical rebates are calculated. So, what does that mean? For context: beginning January 1, 2026, CMS is…
The final installment of a three-part series by Sam Warman Vice President of Client Consulting at Gateway Health Partners on understanding and optimizing medical rebates. Unlocking the Value of Medical Rebates As the number of specialty medications utilized in a healthcare setting continues to grow, so does the need for strategies to control costs and…
Part two of a three-part series by Sam Warman Vice President at Gateway Health Partners on understanding and optimizing medical rebates. Since medical rebates began, they have grown to become essential in offsetting the costs of specialty drugs administered in a clinical setting. Historically, because the use of these specialty medications falls under a patient’s…
Part one of a three-part series on understanding and optimizing medical rebates by Sam Warman Vice President of Client Consulting at Gateway Health Partners. Since medical rebate programs began, they’ve grown to become essential in offsetting the rising costs of specialty medications administered outside of a pharmacy setting. Despite this fact, many plan sponsors may…